Featured Research

from universities, journals, and other organizations

New Technique In Treating Patients With Liver Cancer Proves Effective, Study Suggests

Date:
April 15, 2008
Source:
American Roentgen Ray Society
Summary:
Use of multipolar radiofrequency ablation in the treatment of colorectal liver metastases is effective and has a relatively low recurrence rate, according to a recent study.

Use of multipolar radiofrequency ablation in the treatment of colorectal liver metastases is effective and has a relatively low recurrence rate, according to a recent study conducted by researchers at Charitι, Campus Benjamin Franklin in Berlin, Germany.

"Radiofrequency ablation (RFA) has become a widely used treatment option for patients with primary liver cancer and liver metastases from some primary tumors, if surgery is not an option. However, because of limited sizes of the ablation zones the technique has been limited to tumors smaller than four centimeters," said Bernd Frericks, MD, lead author of the study. "This long-term study (four years) was performed using a new multipolar radiofrequency (RF)-device allowing for up to six ablation probes to be used simultaneously, thus providing larger ablation zones. We evaluated this new technique prospectively regarding ablation zone size, technical effectiveness, complications and clinical outcome in patients with colorectal liver metastases," he said.

The study evaluated 27 patients with 67 colorectal liver metastases that were treated using multipolar RF ablation. According to the study, complete tumor destruction occurred in 66 of 67 cases. Of the 67 metastases, eight required reablation. After a mean of nine months, 16 patients developed new metastases in the liver and the lung, eight of which were successfully reablated. After four years, 52% of the patients are now tumor-free and 78% are still living.

"Using this new device, the rate of local tumor progressions was not influenced by the size of the tumor to be treated," said Dr. Frericks.

The full results of this study will be presented on Wednesday, April 16, 2008 during the American Roentgen Ray Society's annual meeting in Washington, DC.


Story Source:

The above story is based on materials provided by American Roentgen Ray Society. Note: Materials may be edited for content and length.


Cite This Page:

American Roentgen Ray Society. "New Technique In Treating Patients With Liver Cancer Proves Effective, Study Suggests." ScienceDaily. ScienceDaily, 15 April 2008. <www.sciencedaily.com/releases/2008/04/080411150859.htm>.
American Roentgen Ray Society. (2008, April 15). New Technique In Treating Patients With Liver Cancer Proves Effective, Study Suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/04/080411150859.htm
American Roentgen Ray Society. "New Technique In Treating Patients With Liver Cancer Proves Effective, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2008/04/080411150859.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins